Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia
Wirth, Eva K.
Ruis, Silvia Busquets
von Haehling, Stephan
Argiles, Josep M.
Anker, Stefan D.
AffiliationCharité Medical School
Universitat de Barcelona
University of Leipzig
IRCCS San Raffaele, Rome
MetadataShow full item record
AbstractCachexia is a common co-morbidity in cancer occurring in up to 80% of patients depending on the type of cancer. Uric acid (UA), the end-product of the purine metabolism, is elevated in cachexia due to tissue wasting and upregulated xanthine oxidase (XO) activity. High serum UA levels indicate increased XO-dependent production of oxygen free radicals (reactive oxygen species; ROS) and correlate with metabolic illness and poor survival. We hypothesized that XO-inhibition might reduce inflammatory signals accounting for tissue wasting and improve survival in experimental cancer cachexia. Animals were inoculated intraperitoneally with AH-130 hepatoma cells and treated with two XO-inhibitors: allopurinol [Allo, low (LD) and high dose (HD) 4 and 40 mg/kg/d] and its more effective active metabolite oxypurinol (Oxy, 4 and 40 mg/kg/d) or placebo for 15 days. Weight loss and tissue wasting of both fat and lean tissue (assessed by NMR-scanning) was reduced by both LD and HD Allo and LD-Oxy, but not by HD-Oxy. A robust induction of XO-activity for generation of reactive oxygen species was seen in the placebo group (assessed by electron paramagnetic spectroscopy), which was reduced by XO-inhibition. Increased ROS induced cytokine signaling, proteolytic activity and tissue degradation were all attenuated by XO inhibition. Survival was significantly and dose dependently improved. Food intake and spontaneous locomotor activity were higher, indicating a higher quality of life. Inhibition of XO can reduce tissue wasting and improve survival in cancer cachexia and clearly clinical studies are needed.
CitationSpringer, J., et al (2012) 'Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia' Int. J. Cancer 131 (9):2187-96
JournalInternational journal of cancer
- The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy.
- Authors: Springer J, Tschirner A, Hartman K, von Haehling S, Anker SD, Doehner W
- Issue date: 2013 Oct 9
- Eicosapentaenoic acid and oxypurinol in the treatment of muscle wasting in a mouse model of cancer cachexia.
- Authors: Vaughan VC, Sullivan-Gunn M, Hinch E, Martin P, Lewandowski PA
- Issue date: 2012
- Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production.
- Authors: Malik UZ, Hundley NJ, Romero G, Radi R, Freeman BA, Tarpey MM, Kelley EE
- Issue date: 2011 Jul 1
- Rosiglitazone reduces body wasting and improves survival in a rat model of cancer cachexia.
- Authors: Trobec K, Palus S, Tschirner A, von Haehling S, Doehner W, Lainscak M, Anker SD, Springer J
- Issue date: 2014 Sep
- Tandospirone reduces wasting and improves cardiac function in experimental cancer cachexia.
- Authors: Elkina Y, Palus S, Tschirner A, Hartmann K, von Haehling S, Doehner W, Mayer U, Coats AJ, Beadle J, Anker SD, Springer J
- Issue date: 2013 Dec 10